



2018 DISCLOSURE OF INTEREST INFORMATION

GINA BOARD OF DIRECTORS

Louis-Philippe Boulet MD - *Chair*

Eric D. Bateman, MD

Guy Brusselle, MD, PhD, FERS

Alvaro A. Cruz, MD

Mark FitzGerald, MD

Hiromasa Inoue, MD

Mark L. Levy, MD

Jiangtao Lin, MD

Soren Erik Pedersen, MD - *Chair*

Helen K. Reddel, MBBS, PhD

Arzu Yorgancioglu, MD

GINA SCIENCE COMMITTEE

Helen K. Reddel, MBBS, PhD - *Chair*

Len Bacharier, MD

Eric D. Bateman, MD

Louis-Philippe Boulet MD

Guy Brusselle, MD, PhD, FERS

Dr. Roland Buhl

Mark FitzGerald, MD

Louise Fleming, MD

Hiromasa Inoue, MD

Jerry A. Krishnan, MD, PhD

Soren Erik Pedersen, MD

Aziz Sheikh, MD

Dr Fanny Wai-san Ko

GLOBAL INITIATIVE FOR ASTHMA (GINA) DISCLOSURE OF FINANCIAL INTEREST

January 1, 2018 - December 31, 2018

Background

The Global Initiative for Asthma (GINA) program is a collaboration between the scientific community and the private sector. The major objectives are: (1) to increase awareness of asthma among health professionals, health authorities, and the general public; (2) improve diagnosis, management, and prevention; and (3) stimulate research. These objectives are being met through preparation of scientific reports on asthma, dissemination and adoption of recommendations in these reports, and promotion of international collaboration on asthma research.

The purpose of this document is to safeguard the interests of all GINA collaborators by an open disclosure of interests.

GINA Structure

At present, the GINA program is conducted through a GINA Board of Directors that meets annually (usually in January), a Scientific Committee and a Dissemination Committee. Each Committee will have an active role in reviewing and recommending content for GINA documents and all members will be asked to complete this form.

Annual Declaration of Interests

The following declarations are requested by GINA. Please complete the company name select in the corresponding box whether you have financial relationships (received grants, personal fees, shares, non-financial support, other). Please include all companies in the bio-medical arena, as well as telehealth/technology, and tobacco entities. This form will be posted on the GINA website after completion.

Definitions:

1. **Grants:** refers to any grant paid to your organization.
2. **Personal Fees:** refers to honorarium, consultation fees, etc for lectures, advisory committees or consultancy services either intermittent or regular, from which a GINA member benefits personally. This includes ongoing attendance at advisory board meetings but would not normally include a situation where an individual is paid for a specific item or for attending or speaking at an occasional meeting.
3. **Shares:** refers to any shares in asthma-related commercial organizations, excluding unit trusts, pension plans or mutual funds, and it refers to shares held by a GINA member or family members (spouse/children). The company is to be listed, not the number of shares.
4. **Non-Financial Support:** In-kind assistance.

The private sector should not in any way be involved in any aspect of developing documents, including collecting, reviewing or accessing the literature or determining the content. Once documents have been produced asthma-related commercial organizations can be involved in their dissemination and audit, including support for publications.

**GLOBAL INITIATIVE FOR ASTHMA (GINA)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Louis-Philippe BOULET

Member of: Chair of the Board of Directors of the GINA
Chair of the Global Initiative for Asthma (GINA Guidelines) Dissemination and Implementation Committee

Are there any relevant financial interests to disclose?

Here are some potential COI for 2018

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
AstraZeneca	x				Research grants for participation to multicentre
Boston Scientific	x				Research grants for participation to multicentre
GlaxoSmithKline	x				Research grants for participation to multicentre
Hoffman La Roche	x				Research grants for participation to multicentre
Novartis	x				Research grants for participation to multicentre
Ono Pharma	x				Research grants for participation to multicentre
Sanofi Takeda	x				Research grants for participation to multicentre
AstraZeneca		x			Consulting and advisory boards
Novartis		x			Consulting and advisory boards
Methapharm		x			Consulting and advisory boards
AstraZeneca		x			Conference fees
GlaxoSmithKline		x			Conference fees
Merck Frosst		x			Conference fees
Novartis		x			Conference fees
Novartis		x			Support for participation in conferences and meetings
Takeda		x			Support for participation in conferences and meetings
AstraZeneca			x		Nonprofit grants for production of educational materials
Boehringer-Ingelheim			x		Nonprofit grants for production of educational materials
GlaxoSmithKline			x		Nonprofit grants for production of educational materials
Merck Frosst			x		Nonprofit grants for production of educational materials
Novartis			x		Nonprofit grants for production of educational materials

**GLOBAL INITIATIVE FOR ASTHMA (GINA)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Professor Eric D Bateman

Member of: GINA Board of Directors, GINA Science Committee

Are there any relevant financial interests to disclose? Yes; see below

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
Novartis		yes			Advisory board
Sanofi-Aventis		yes			Advisory board
ALK		yes			Consultancy & Lecture fee
ICON		yes			Study oversight steering committee
Regeneron		yes			Advisory board
AstraZeneca		yes			Advisory board & lecture fees
Boehringer Ingelheim		yes			Lecture fee

DISCLOSURE OF FINANCIAL INTEREST

Name: Mark FitzGerald, MD

Member of: GINA Board of Directors, GINA Science Committee

Are there any relevant financial interests to disclose? Yes; see below

1. PERSONAL BENEFITS*

Includes fees (for lectures, advisory committees, travel grants, or consultancy services) either intermittent or regular, from which you benefit personally.

Company	< \$10,000	> \$10,000	Nature/Purpose of Payment
BI	X		Advisory board
GSK	X		Consulting for study design
AZ		X	Lectures, advisory board,
Novartis	X		Advisory board and lecture fees
Teva	X		Advisory board
Merck	X		Lecture fees

* Check category only; do not list the amount received.

2. SHARES*

Includes shares in the asthma related pharmaceutical/medical device industry, excluding pension plans, mutual funds or unit trusts, held by a GINA member or family members (spouse and children < 18 years).

Company	< \$10,000	> \$10,000
None		

*Check category only; do not list the number of shares or \$ amount.

3. NON-PERSONAL INTERESTS*

Includes fees or grants paid to a GINA member and used for research, education, equipment, salaries, etc.

Company	< \$10,000	> \$10,000	Nature/Purpose of Support
AZ		X	Research funds paid directly to UBC for all companies and all greater than \$10,000
GSK			
Merck			
Novartis			
Sanofi			

* Check category only; do not list amount of funding received.

I confirm that these forms are complete.

Name: _____

(Choose one or both)

____ GINA Board of Directors

____ GINA Science Committee

Signature: _____

Date: _____

**GLOBAL INITIATIVE FOR ASTHMA (GINA)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Helen Reddel

Member of: GINA Board of Directors, GINA Science Committee

Are there any relevant financial interests to disclose? Yes

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
AstraZeneca	Yes	Yes	Yes	No	Advisory boards, steering committee, DSMB, independent medical education, medical writing support
Boehringer Ingelheim	No	Yes	No	No	Independent medical education
GlaxoSmithKline	Yes	Yes	No	No	DSMB
Merck	No	Yes	No	No	DSMB
Novartis	No	Yes	No	No	DSMB, advisory board

**GLOBAL INITIATIVE FOR ASTHMA (GINA)
DISCLOSURE OF FINANCIAL INTEREST**



Name: Dr. Louise Fleming

Member of: GINA Science Committee

Are there any relevant financial interests to disclose? Yes

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Comments:
Novartis	<input type="checkbox"/>				Attendance at standalone advisory boards and payment for lectures; all fees paid to institution
GSK	<input type="checkbox"/>				Attendance at standalone advisory boards; all fees paid to institution
Boehringer Ingelheim	<input type="checkbox"/>				Attendance at standalone advisory boards and payment for lectures; all fees paid to institution
Teva	<input type="checkbox"/>				Payment for lecture; all fees paid to institution
Astra Zeneca	<input type="checkbox"/>				Payment for lecture; all fees paid to institution
Sanofi	<input type="checkbox"/>				Attendance at standalone advisory boards; all fees paid to institution
Respiri UK	<input type="checkbox"/>				Attendance at standalone advisory boards; all fees paid to institution

